Mitobronitol
|
WikiDoc Resources for Mitobronitol |
|
Articles |
|---|
|
Most recent articles on Mitobronitol Most cited articles on Mitobronitol |
|
Media |
|
Powerpoint slides on Mitobronitol |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Mitobronitol at Clinical Trials.gov Clinical Trials on Mitobronitol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Mitobronitol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Mitobronitol Discussion groups on Mitobronitol Patient Handouts on Mitobronitol Directions to Hospitals Treating Mitobronitol Risk calculators and risk factors for Mitobronitol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Mitobronitol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mitobronitol (1,6-dibromo-1,6-dideoxy-D-mannitol) is a brominated analog of mannitol. It is an anticancer drug that is classified as an alkylating agent.[1]
References
- ↑ Mitobronitol, The Centre for Cancer Education